Foresite Capital Management IV, LLC Diversified Active

CIK: 0001704132 · Show all filings

Period: Q1 2024 (← Previous) (Next →)

Filing Date: May 15, 2024

Total Value ($000): $197,913 (100.0% shares, 0.0% debt)

Holdings (5)

PHVS Pharvaris N.V. 47.2%

Value ($000) $93,338 Shares 4,038,842 Est. Cost $27.96 Unrealized -5.0%

KURA Kura Oncology, Inc. 19.9%

Value ($000) $39,459 Shares 1,849,947 Est. Cost $20.39 Unrealized -4.6%

— Kinnate Biopharma Inc. 13.0%

Value ($000) $25,727 Shares 9,671,643 Est. Cost $39.78 Unrealized —

SNDX Syndax Pharmaceuticals, Inc. 10.5%

Value ($000) $20,825 Shares 875,000 Est. Cost $22.62 Unrealized -1.4%

— Lyell Immunopharma, Inc. 9.4%

Value ($000) $18,565 Shares 8,325,000 Est. Cost $16.24 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
PHVS	Pharvaris N.V.	4,038,842	$93,338	47.2%	$27.96	-5.0%	COM	N69605108
KURA	Kura Oncology, Inc.	1,849,947	$39,459	19.9%	$20.39	-4.6%	COM	50127T109
—	Kinnate Biopharma Inc.	9,671,643	$25,727	13.0%	$39.78	—	COM	49705R105
SNDX	Syndax Pharmaceuticals, Inc.	875,000	$20,825	10.5%	$22.62	-1.4%	COM	87164F105
—	Lyell Immunopharma, Inc.	8,325,000	$18,565	9.4%	$16.24	—	COM	55083R104